Optimal Duration of Treatment With Eculizumab in Atypical Hemolytic Uremic Syndrome (aHUS)—a Question to Be Addressed in a Scientific Way
Pediatric Nephrology - Germany
doi 10.1007/s00467-019-4192-7
Full Text
Open PDFAbstract
Available in full text
Date
January 28, 2019
Authors
Publisher
Springer Science and Business Media LLC